CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 87.41% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Scan to Download iOS&Android APP

Trade Turning Point Therapeutics, Inc. - TPTX CFD

75.93
0.68%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.15
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.0308 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.0308%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.0308 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.0137%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 75.42
Open* 75.92
1-Year Change* N/A
Day's Range* 75.91 - 75.91
52 wk Range 23.77-82.2
Average Volume (10 days) N/A
Average Volume (3 months) 40.6406
Market Cap 3806.15
P/E Ratio N/A
Shares Outstanding 50074300
Revenue 1.008
EPS -6.90372
Dividend (Yield %) N/A
Beta -0.20154
Next Earnings Date Nov 7, 2022

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Aug 16, 2022 75.93 0.01 0.01% 75.92 75.93 75.91
Aug 15, 2022 75.42 0.18 0.24% 75.24 75.70 75.24
Aug 12, 2022 75.34 0.48 0.64% 74.86 75.62 74.86
Aug 11, 2022 74.91 -0.03 -0.04% 74.94 75.04 74.82
Aug 10, 2022 74.95 0.04 0.05% 74.91 75.08 74.79
Aug 9, 2022 74.96 0.03 0.04% 74.93 75.07 74.51
Aug 8, 2022 75.00 0.06 0.08% 74.94 75.12 74.89
Aug 5, 2022 74.89 -0.15 -0.20% 75.04 75.32 74.87
Aug 4, 2022 75.18 0.12 0.16% 75.06 75.22 74.92
Aug 3, 2022 75.12 0.33 0.44% 74.79 75.16 74.75
Aug 2, 2022 74.69 -0.17 -0.23% 74.86 75.11 74.66
Aug 1, 2022 74.87 -0.03 -0.04% 74.90 74.97 74.80
Jul 29, 2022 74.92 -0.13 -0.17% 75.05 75.15 74.85
Jul 28, 2022 75.20 0.29 0.39% 74.91 75.26 74.91
Jul 27, 2022 74.94 0.08 0.11% 74.86 75.09 74.84
Jul 26, 2022 74.78 -0.06 -0.08% 74.84 74.92 74.76
Jul 25, 2022 74.92 0.07 0.09% 74.85 74.92 74.75
Jul 22, 2022 74.92 0.23 0.31% 74.69 74.92 74.60
Jul 21, 2022 74.71 0.10 0.13% 74.61 74.71 74.51
Jul 20, 2022 74.91 0.22 0.29% 74.69 74.97 74.67

Turning Point Therapeutics, Inc. Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2017 2018 2019 2020 2021
Total revenue 0 0 0 25 30.829
Total Operating Expense 16.728 25.64 77.724 186.836 268.829
Selling/General/Admin. Expenses, Total 1.487 4.578 19.781 73.425 75.85
Research & Development 15.241 21.062 57.943 113.411 192.979
Operating Income -16.728 -25.64 -77.724 -161.836 -238
Interest Income (Expense), Net Non-Operating 0.136 0.856 5.593 0
Net Income Before Taxes -16.592 -24.784 -72.131 -157.292 -236.551
Net Income After Taxes -16.593 -24.785 -72.131 -157.292 -236.551
Net Income Before Extra. Items -16.593 -24.785 -72.131 -157.292 -236.551
Total Extraordinary Items 0
Net Income -16.593 -24.785 -72.131 -157.292 -236.551
Income Available to Common Excl. Extra. Items -16.593 -24.785 -72.131 -157.292 -236.551
Income Available to Common Incl. Extra. Items -16.593 -24.785 -72.131 -157.292 -236.551
Diluted Net Income -16.593 -24.785 -72.131 -157.292 -236.551
Diluted Weighted Average Shares 29.6547 29.6547 24.1249 40.8438 49.2645
Diluted EPS Excluding Extraordinary Items -0.55954 -0.83579 -2.9899 -3.85106 -4.80165
Diluted Normalized EPS -0.55954 -0.83579 -2.9899 -3.85106 -4.80165
Revenue 25 30.829
Other, Net 4.544 1.449
Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022
Total revenue 25.205 5.164 0.46 0 0.429
Revenue 25.205 5.164 0.46 0 0.429
Total Operating Expense 61.254 61.821 67.113 78.641 75.364
Selling/General/Admin. Expenses, Total 19.991 17.171 18.224 20.464 20.314
Research & Development 41.263 44.65 48.889 58.177 55.05
Operating Income -36.049 -56.657 -66.653 -78.641 -74.935
Other, Net 0.545 0.384 0.328 0.192 0.49
Net Income Before Taxes -35.504 -56.273 -66.325 -78.449 -74.445
Net Income After Taxes -35.504 -56.273 -66.325 -78.449 -74.445
Net Income Before Extra. Items -35.504 -56.273 -66.325 -78.449 -74.445
Net Income -35.504 -56.273 -66.325 -78.449 -74.445
Income Available to Common Excl. Extra. Items -35.504 -56.273 -66.325 -78.449 -74.445
Income Available to Common Incl. Extra. Items -35.504 -56.273 -66.325 -78.449 -74.445
Diluted Net Income -35.504 -56.273 -66.325 -78.449 -74.445
Diluted Weighted Average Shares 48.9204 49.2044 49.4265 49.5011 49.6115
Diluted EPS Excluding Extraordinary Items -0.72575 -1.14366 -1.34189 -1.58479 -1.50056
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.72575 -1.14366 -1.34189 -1.58479 -1.50056
  • Annual
  • Quarterly
2017 2018 2019 2020 2021
Total Current Assets 45.614 101.523 414.947 1130.68 992.462
Cash and Short Term Investments 45.033 101.029 409.151 1122.51 981.582
Cash & Equivalents 45.033 101.029 48.188 554.101 427.879
Prepaid Expenses 0.581 0.494 5.796 8.171 10.88
Total Assets 45.908 103.28 422.202 1136.71 1003.46
Property/Plant/Equipment, Total - Net 0.256 1 7.182 5.961 8.98
Property/Plant/Equipment, Total - Gross 0.392 1.271 7.753 7.407 11.635
Accumulated Depreciation, Total -0.136 -0.271 -0.571 -1.446 -2.655
Other Long Term Assets, Total 0.038 0.757 0.073 0.073 2.021
Total Current Liabilities 4.525 5.322 14.032 24.392 47.089
Accounts Payable 1.339 1.494 2.15 5.225 5.656
Accrued Expenses 3.161 3.638 11.837 19.123 41.285
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0.025 0.19 0.045 0.044 0.148
Total Liabilities 4.591 5.77 17.851 26.815 49.038
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 0.066 0.448 3.819 2.423 1.949
Total Equity 41.317 97.51 404.351 1109.9 954.425
Preferred Stock - Non Redeemable, Net 66.161 145.916 0 0 0
Common Stock 0.001 0.001 0.004 0.005 0.005
Additional Paid-In Capital 1.123 2.346 526.96 1389.86 1472.42
Retained Earnings (Accumulated Deficit) -25.968 -50.753 -122.884 -280.176 -516.727
Total Liabilities & Shareholders’ Equity 45.908 103.28 422.202 1136.71 1003.46
Total Common Shares Outstanding 29.6547 29.6547 35.9151 48.6785 49.5826
Short Term Investments 360.963 568.407 553.703
Other Equity, Total 0.271 0.209 -1.274
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 1121.91 1091.42 1047.14 992.462 927.431
Cash and Short Term Investments 1114.78 1077.81 1036.01 981.582 918.187
Cash & Equivalents 469.167 426.047 404.203 427.879 309.532
Short Term Investments 645.61 651.759 631.811 553.703 608.655
Prepaid Expenses 7.135 13.614 11.127 10.88 9.244
Total Assets 1127.58 1102.92 1058.98 1003.46 938.786
Property/Plant/Equipment, Total - Net 5.565 9.479 9.823 8.98 9.314
Property/Plant/Equipment, Total - Gross 7.264 11.443 12.115 11.635 12.357
Accumulated Depreciation, Total -1.699 -1.964 -2.292 -2.655 -3.043
Other Long Term Assets, Total 0.107 2.021 2.021 2.021 2.041
Total Current Liabilities 24.371 31.895 38.753 47.089 45.566
Accounts Payable 6.784 7.088 3.188 5.656 7.61
Accrued Expenses 17.557 24.723 35.487 41.285 37.764
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0.03 0.084 0.078 0.148 0.192
Total Liabilities 26.419 35.413 41.648 49.038 47.439
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 2.048 3.518 2.895 1.949 1.873
Total Equity 1101.17 1067.51 1017.34 954.425 891.347
Common Stock 0.005 0.005 0.005 0.005 0.005
Additional Paid-In Capital 1416.82 1439.45 1455.63 1472.42 1487.91
Retained Earnings (Accumulated Deficit) -315.68 -371.953 -438.278 -516.727 -591.172
Other Equity, Total 0.023 0.002 -0.016 -1.274 -5.392
Total Liabilities & Shareholders’ Equity 1127.58 1102.92 1058.98 1003.46 938.786
Total Common Shares Outstanding 49.117 49.3917 49.4642 49.5826 49.6645
Preferred Stock - Non Redeemable, Net 0 0 0
  • Annual
  • Quarterly
2017 2018 2019 2020 2021
Net income/Starting Line -16.593 -24.785 -72.131 -157.292 -236.551
Cash From Operating Activities -12.64 -23.533 -57.757 -82.793 -153.885
Cash From Operating Activities 0.052 0.138 0.492 0.875 1.209
Non-Cash Items 0.342 1.107 12.436 66.942 66.648
Cash Taxes Paid 0.001 0.001 0.001 0.001 0.001
Changes in Working Capital 3.559 0.007 1.446 6.682 14.809
Cash From Investing Activities -0.088 -0.302 -361.079 -210.032 5.462
Capital Expenditures -0.088 -0.302 -1.744 -1.264 -2.427
Cash From Financing Activities 44.851 79.831 365.995 798.738 24.004
Issuance (Retirement) of Stock, Net 44.851 79.831 176.49 13.269 24.004
Net Change in Cash 32.123 55.996 -52.841 505.913 -124.419
Other Investing Cash Flow Items, Total -359.335 -208.768 7.889
Financing Cash Flow Items 189.505 785.469 0
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line -35.504 -91.777 -158.102 -236.551 -74.445
Cash From Operating Activities -15.648 -58.069 -99.734 -153.885 -58.331
Cash From Operating Activities 0.253 0.518 0.846 1.209 0.393
Non-Cash Items 19.058 34.309 50.307 66.648 16.843
Cash Taxes Paid 0.001 0.001 0.001 0.001 0
Changes in Working Capital 0.545 -1.119 7.215 14.809 -1.122
Cash From Investing Activities -78.931 -87.203 -69.76 5.462 -60.412
Capital Expenditures -0.143 -0.874 -2.04 -2.427 -0.447
Other Investing Cash Flow Items, Total -78.788 -86.329 -67.72 7.889 -59.965
Cash From Financing Activities 9.679 19.02 21.399 24.004 0.396
Issuance (Retirement) of Stock, Net 9.679 19.02 21.399 24.004 0.396
Net Change in Cash -84.9 -126.252 -148.095 -124.419 -118.347
Financing Cash Flow Items 0 0

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
475000+

Traders

71000+

Active clients monthly

$51000000+

Monthly investing volume

$30000000+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

Turning Point Therapeutics, Inc. Company profile

About Turning Point Therapeutics Inc

Turning Point Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in designing and developing therapies that target genetic drivers of cancer to improve the lives of patients. It develops a macrocycle platform from which it designs its pipeline of small, compact tyrosine kinase inhibitors (TKIs). The TKIs generated from its drug discovery platform address unmet needs in TKI naive and resistance settings. The Company’s drug candidate, repotrectinib (TPX-0005), is in Phase I/II trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with NTRK+ or ALK+ advanced solid tumors. Its multi-cohort Phase II registrational portion of TRIDENT-1 is ongoing at sites in North America, Europe and the Asia-Pacific regions. The Company’s pipeline includes multi-targeted kinase inhibitors: TPX-0046 (a novel RET inhibitor), Elzovantinib (TPX-0022) (a novel MET/CSF1R/SRC inhibitor) and TPX-0131.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Turning Point Therapeutics Inc revenues increased 23% to $30.8M. Net loss increased 50% to $236.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Pharmaceutical Preparations segment loss increase of 47% to $238M. Basic Earnings per Share excluding Extraordinary Items decreased from -$3.85 to -$4.80.

Industry: Bio Therapeutic Drugs

10628 Science Center Drive, Suite 200
SAN DIEGO
CALIFORNIA 92121
US

Income Statement

People also watch

Oil - Crude

81.09 Price
-0.230% 1D Chg, %
Long position overnight fee -0.0098%
Short position overnight fee -0.0039%
Overnight fee time 22:00 (UTC)
Spread 0.03

US100

11,997.50 Price
-0.130% 1D Chg, %
Long position overnight fee -0.0166%
Short position overnight fee 0.0059%
Overnight fee time 22:00 (UTC)
Spread 1.8

BTC/USD

16,972.35 Price
+0.100% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 60.00

Natural Gas

6.66 Price
-2.460% 1D Chg, %
Long position overnight fee 0.0429%
Short position overnight fee -0.0679%
Overnight fee time 22:00 (UTC)
Spread 0.005

Still looking for a broker you can trust?

Join the 475.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading